Fig. 3From: Comparison of immune checkpoint inhibitors related to pulmonary adverse events: a retrospective analysis of clinical studies and network meta-analysisHeat maps of risk for each treatment regimen at different grades of PAEs. In particular, treatment regimens were ranked according to all-grade PAEs, grades 3–4 PAEs, and grade 5 PAEs. The numbers in the squares represent the surface under the cumulative ranking curve (SUCRA) values. These values are measured using a scale from 0 (worst) to 100 (best). The SUCRA value is inversely proportional to the risk of adverse eventsBack to article page